Direct Is Not One Model: Rethinking How Aesthetics Brands Enter the UK

Executive summary

For many aesthetics manufacturers, direct is the preferred long-term model because it provides greater control over the clinic relationship, CRM, education, pricing, market intelligence and brand development.

But direct does not necessarily mean doing everything yourself. Sales, marketing and customer ownership can remain with the manufacturer while a wholesaler, pharmacy partner or third-party logistics provider handles stock, credit, storage and fulfilment.

Distribution provides another route. A distributor typically buys stock and resells it, taking greater commercial risk but also gaining greater independence over how it develops the market. An agent operates differently, selling on behalf of the manufacturer rather than purchasing and reselling the product. Consignment and hybrid arrangements create further options between these models. [1]

The strategic question for a manufacturer entering the UK is therefore less “direct or distributor?” and more “what do we need to own?”

That includes the customer relationship, demand generation, sales execution, education, stock risk and fulfilment. The right answer will depend on the product, the manufacturer’s resources and where it wants the UK business to be in three to five years.

Direct is not one model

The language around direct sales can be misleading.

A manufacturer does not need its own warehouse, pharmacy operation and logistics network simply because it wants its own sales team.

A third-party logistics provider can manage storage and fulfilment while the brand retains its commercial relationship with the customer. An agent can represent the manufacturer while the customer continues to contract with the manufacturer. Under a traditional distribution model, by contrast, the distributor normally purchases the goods and resells them to the customer. Wilson Browne notes that agency can allow suppliers to retain greater control over pricing, customers and marketing, while distribution transfers more financial risk to the distributor. [1] Wilson Browne

This creates a spectrum rather than a binary choice. A manufacturer might start with a distributor, move towards a hybrid model as sales increase, retain a pharmacy or wholesale partner for fulfilment, and eventually take direct control of sales and customer data without ever bringing logistics fully in-house.

The question is not simply who moves the box. It is who owns the commercial relationship around it.

Who actually builds the market?

This is one of the more important distinctions when assessing a distributor.

A distributor may have strong clinic relationships, an established sales team and significant operational infrastructure, but it will normally represent multiple products. A new brand therefore enters an existing portfolio, promotional calendar and set of commercial priorities.

Availability should not be confused with demand generation.

Someone still needs to educate customers, develop advocates, run launches, generate leads, train the sales force and ensure the product remains a priority after the initial introduction.

This means manufacturers should understand both the responsibility and the authority within the relationship. If the distributor is responsible for sales but the manufacturer controls the marketing budget, if the manufacturer wants a launch accelerated but the distributor has other priorities, or if neither party clearly owns CRM and customer development, accountability quickly becomes blurred.

For a new entrant, the more revealing question may therefore be: if sales are below plan six months after launch, who is expected to fix it?

Why brands still want to get closer to customers

The attraction of commercial ownership can be seen in several established businesses.

Establishment Labs moved its UK business from a hybrid model to a fully direct sales force in 2018, citing closer surgeon engagement, greater control over sales and marketing and better management of major-account inventory. [2] Establishment Labs

More recently, when Bridgepoint announced its agreement to acquire Obagi Medical in June 2026, it specifically highlighted the expansion of Obagi’s direct-to-physician business as part of the company's recent growth and profitability improvement. [3] Bridgepoint Corporate2022

The logic is straightforward. The closer a manufacturer gets to the practitioner, the more directly it can understand purchasing behaviour, feedback, education needs and opportunities for additional products.

But greater control also means greater fixed cost.

Devices show where direct becomes harder

Energy-based devices expose that trade-off particularly clearly.

Sciton established direct UK and Ireland operations in 2020, bringing marketing, sales, clinical education and service under its own organisation. [4] Sciton

Cynosure Lutronic currently illustrates another approach. Seriderm describes itself as Cynosure Lutronic's exclusive partner in the UK and Ireland, providing the devices through a specialist local organisation. [5] Seriderm UK

Both models can make commercial sense.

A device manufacturer operating directly may need salespeople, clinical trainers, demonstration equipment, technical support and engineers. Those costs are relatively fixed, while capital-equipment revenue can be uneven. A handful of purchasing decisions moving between months or quarters can materially alter performance.

Laseraid UK provides a recent reminder of the financial pressures that can exist within the category. The company entered administration on 30 April 2025, with the administration ending in April 2026 as the company moved towards dissolution. [6] That does not establish that its route-to-market model caused its difficulties, but it does illustrate the vulnerability of businesses carrying infrastructure against less predictable capital-equipment revenue. Companies House

For manufacturers, the decision is therefore not only about retaining distributor margin. It is about whether the market can support the infrastructure required to earn that margin directly.

Distribution is evolving too

There is also a danger in assuming the distributor is simply an intermediary taking a percentage between manufacturer and clinic.

The stronger operators increasingly combine product supply with pharmacy, training, education, customer service and other clinic support.

DD Group's acquisition of Fox Pharma in February 2026 is a useful example. DD said the acquisition strengthened its aesthetics offering and expanded its training and clinic-support capabilities across the UK and Ireland. [7] DD Group

That makes the economics more complicated. Replacing a distributor may mean replacing not only salespeople, but elements of customer service, credit, logistics, education and market access.

Equally, a manufacturer does not have to replace all of those functions. Logistics can remain outsourced while sales come in-house, pharmacy can remain external while the manufacturer owns CRM, and an agent can provide commercial reach without taking ownership of the stock.

That flexibility is probably where the UK market becomes most interesting.

The Harley View

The UK should not be thought of as inherently a direct market or a distributor market.

It is better viewed as a collection of commercial functions that can be assembled in different ways.

For a manufacturer testing the UK, a distributor may provide the fastest route to market with lower fixed cost and access to existing customer relationships. As the brand grows, the value of owning CRM, education and customer development may increase. At that point, a hybrid or commercially direct model can become more attractive without requiring the manufacturer to replicate every operational capability itself.

The critical distinction is between outsourcing infrastructure and outsourcing the customer.

A manufacturer may be comfortable outsourcing warehousing, pharmacy and fulfilment for many years. It may be far less comfortable outsourcing customer knowledge, sales strategy and demand generation indefinitely.

That is why route-to-market decisions should probably begin with the end state.

Where does the brand want to be in the UK in five years, which parts of that business are strategically important to own, and who will be accountable for building the market between now and then?

A distributor can be the right route into the UK without necessarily being the permanent route through it. Direct can be the long-term ambition without being the right place to start.

References

[1] Wilson Browne Solicitors — A Guide to Agency & Distribution Agreements
Explains the commercial distinction between agency and distribution, including pricing control, customer relationships and stock/commercial risk.
https://www.wilsonbrowne.co.uk/business/commercial/guides/agency-distributorship/

[2] Establishment Labs — Transition to a Direct Sales Force in the United Kingdom
Establishment Labs announced its move from a hybrid model to a fully direct UK sales structure, citing closer surgeon engagement and greater control over sales and marketing.
https://investors.establishmentlabs.com/press-releases/press-releases-details/2018/Establishment-Labs-announces-transition-to-a-Direct-Sales-Force-in-the-United-Kingdom/default.aspx

[3] Bridgepoint — Agreement to Acquire Obagi Medical
Bridgepoint highlighted the expansion of Obagi’s direct-to-physician business as part of the company’s growth and profitability development.
https://www.bridgepointgroup.com/about-us/news-and-insights/press-releases/2026/bridgepoint-agrees-to-acquire-obagi-medical

[4] Sciton — Launch of Direct Operations in the United Kingdom
Sciton announced direct UK and Ireland operations covering sales, marketing, clinical education and service.
https://sciton.com/sciton-announces-the-launch-of-direct-operations-in-the-united-kingdom/

[5] Seriderm — Cynosure Lutronic UK & Ireland Partnership
Seriderm describes itself as Cynosure Lutronic’s exclusive partner in the UK and Ireland.
https://www.seridermuk.com/

[6] Companies House — Laseraid UK Limited Insolvency Record
Official record showing Laseraid UK entered administration in April 2025 and subsequently moved towards dissolution.
https://find-and-update.company-information.service.gov.uk/company/12894924/insolvency

[7] Companies House — Laseraid International Group Limited
Official company record showing Laseraid International Group Limited in liquidation.
https://find-and-update.company-information.service.gov.uk/company/12888511

[8] DD Group — Acquisition of Fox Pharma
DD Group said its acquisition of Fox Pharma strengthened its aesthetics portfolio and expanded training and clinic-support capabilities.
https://www.ddgroup.com/corporate-news/dd-group-acquires-fox-group-global-ltd/

[9] Healthxchange — UK Aesthetics Supply and Services Platform
Healthxchange operates across injectables, skincare, devices, education and associated clinic-support services.
https://www.healthxchange.com/

[10] SEKO Logistics — Choosing the Right 3PL for Beauty Brands and Cosmetics
Useful operational context on how brands can outsource logistics and fulfilment while retaining the commercial relationship.
https://www.sekologistics.com/emea-en/resource-hub/knowledge-hub/how-to-successfully-onboard-a-3pl-for-beauty-brands-in-the-uk/

[11] Fox Williams — Agent or Distributor: Which Should a Supplier Use?
Additional legal and commercial context on the differences between agency and distribution models.
https://www.foxwilliams.com/2025/09/26/agent-or-distributor-which-should-a-supplier-use/

[12] Taylor Rose — Distributor or Agent?
Further background on the legal and commercial distinctions between using an agent and appointing a distributor.
https://www.taylor-rose.co.uk/posts/agent-or-distributor

Editorial note

Editorial transparency: Company statements about their commercial models, route-to-market structures and capabilities are treated as company-reported information. Legal and logistics sources are used to explain the characteristics of agency, distribution and outsourced fulfilment models. The Harley’s interpretation of what these examples may mean for manufacturers considering the UK market is independent editorial analysis. No single company example is presented as evidence that one route-to-market model is universally superior to another.